James Joye, DO
Interventional Cardiology · Mountain View, CANPI 1396751889
Payments from drug & device makers
Across 132 payments — averaging $1055.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$49K
- Endologix LLC$45K
- Medtronic$36K
- Cordis Corporation$8K
- Smith+Nephew$226
- Organogenesis Inc.$182
- plus $750 from 10 others
What the payments were for
- Consulting fees$33,90035%
- Travel & lodging$6,0596%
- Food & beverage$6,3367%
- Education$19,25020%
- Other$30,00031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $49,276 |
| Endologix LLC | 60 | $44,977 |
| Medtronic(2 entities) | 31 | $36,176 |
| Cordis Corporation | 3 | $7,755 |
| Smith+Nephew | 2 | $226 |
| Organogenesis Inc. | 7 | $182 |
| Bard Peripheral Vascular, Inc. | 1 | $173 |
| Abbott | 4 | $150 |
| Bardy Diagnostics, Inc. | 5 | $123 |
| Boston Scientific | 6 | $111 |
| Baxter Healthcare | 3 | $82 |
| Amgen | 1 | $29 |
| Venclose Inc. | 1 | $24 |
| Cordis US CORP. | 1 | $23 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$49,250
- Torus Stent Graft System$41,525
- ENDOCROSS Device$41,525
- RotarexS 6 F x 135 cm$173
- Grafix PL PRIME$128
- Stravix$128
How this compares
$139,343 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $112,256 |
| Repatha SureclickEvolocumab | 40 | $34,974 |
| XareltoRivaroxaban | 35 | $33,030 |
| EntrestoSacubitril/Valsartan | 30 | $25,628 |
| Praluent PenAlirocumab | 11 | $5,308 |
| ClopidogrelClopidogrel Bisulfate | 346 | $4,846 |
| Metoprolol Succinate | 150 | $2,753 |
| Atorvastatin Calcium | 201 | $2,526 |
| Rosuvastatin Calcium | 118 | $1,782 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $1,470 |
| Potassium Chloride | 58 | $1,251 |
| Ezetimibe | 55 | $1,044 |
| Pantoprazole Sodium | 67 | $700 |
| Losartan Potassium | 59 | $651 |
| Furosemide | 108 | $590 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Mountain View
- Frederick St GoarMountain View$4.2M
- Chidambaram RammohanMountain View$589K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Sammy ElmariahSan Francisco$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.